Registry of Lobbyists

Registration - In-house Corporation

GlaxoSmithKline / Sridhar Venkatesh, General Manager and President

Registration Information

In-house Corporation name: GlaxoSmithKline
Previous in-house corporation names
Responsible Officer Name: Sridhar Venkatesh, General Manager and President 
Responsible Officer Change History
Initial registration start date: 1996-03-25
Registration status: Active
Registration Number: 953603-5088

Associated Communications

Total Number of Communication Reports: 271

Monthly communication reports in the last 6 months: 21

Version 12 of 62 (2008-01-09 to 2008-07-09)

Version 12 of 62 (2008-01-09 to 2008-07-09) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: GlaxoSmithKline
7333 Mississauga Road
Mississauga, ON  L5N 6L4
Canada
Telephone number: 905-819-3000
Fax number: 905-819-3099  
Responsible officer name and position during the period of this registration: Paul Lucas, President and CEO  
Description of activities: GLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN TOTAL GLAXOSMITHKLINE EMPLOYS APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY. GSK IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OPERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY.
 
The client is a subsidiary of the following parent companies: GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW89GS
United Kingdom

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Jacqueline LaRocque
Position title: Manager, Public Policy
Public offices held: Yes
 
Name: Geoff Mitchinson
Position title: Vice President, Public Affairs and Reimbursement
Public offices held: No
 
Name: Doug Nanton
Position title: Manager
Public offices held: No
 
Name: Grant Perry
Position title: Director, Federal Affairs and Reimbursement
Public offices held: Yes
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Atlantic Canada Opportunities Agency (ACOA), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Members of the House of Commons, National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Works and Government Services Canada, Revenue Canada (RC), Technology Partnerships Canada (TPC), Treasury Board Of Canada Secretariat (TBS)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Constitutional Issues, Consumer Issues, Employment and Training, Financial Institutions, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Labour, Regional Development, Science and Technology, Taxation and Finance
 
Subject Matter: Retrospective: ANY LEGISLATIVE PROPOSALS, POLICIES OR PAPERS, BILLS OR RESOLUTIONS, OR REGULATIONS THAT WOULD IMPACT THE BRAND NAME PHARMACEUTICAL INDUSTRY OR THE REVIEW OF ANY DRUG PATENT LEGISLATION; PHARMACARE OR HOME CARE PROGRAMS; NATIONAL PHARMACEUTICALS STRATEGY, DRUG APPROVALS POLICIES AND PROCESSES AS WELL AS GOVERNMENT PURCHASES OF VACCINES.
Subject Matter: Prospective: ANY LEGISLATIVE PROPOSALS, POLICIES OR PAPERS, BILLS OR RESOLUTIONS, OR REGULATIONS THAT WOULD IMPACT THE BRAND NAME PHARMACEUTICAL INDUSTRY OR THE REVIEW OF ANY DRUG PATENT LEGISLATION; PHARMACARE OR HOME CARE PROGRAMS; DRUG APPROVALS POLICIES AND PROCESSES AS WELL AS GOVERNMENT PURCHASES OF VACCINES.
 

Details Regarding the Identified Subject Matter

Categories Description
Policy or Program Common Drug Review
Policy or Program Drug approval times
Policy or Program Federal drug plans
Legislative Proposal Food and Drugs Act renewal
Regulation Health Canada Regulatory environment
Legislative Proposal Income Tax Act (SR&ED)
Policy or Program National Pharmaceuticals Strategy
Policy or Program Pandemic influenza contract
Legislative Proposal Patent Act
Legislative Proposal Patented Medicines Regulation Act, PMPRB mandate
Policy or Program Policy environment for vaccines
Legislative Proposal Review of Canada's Access to Medicines Regime
Regulation Review of Data Protection and Linkage regulations
Policy or Program Science and Techology Strategy (S&T)
Policy or Program Vaccines contracts




Date Modified: